China Biologic Products Holdings Inc Revenue Growth Rates (CBPO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
China Biologic Products Holdings Inc   (NASDAQ: CBPO)
 

CBPO's Revenue Growth by Quarter and Year

China Biologic Products Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CBPO Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December 503.74
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 503.74

CBPOs Annual Revenue
China Biologic Products Holdings Inc 's Revenue in the fiscal year 2019 $ 503.74 millions
China Biologic Products Holdings Inc 's Revenue in the fiscal year 2018 $ 466.88 millions
China Biologic Products Holdings Inc 's Revenue in the fiscal year 2017 $ 370.41 millions
China Biologic Products Holdings Inc 's Revenue in the fiscal year 2016 $ 341.17 millions
China Biologic Products Holdings Inc 's Revenue in the fiscal year 2015 $ 296.46 millions




CBPO Revenue fourth quarter 2019 Y/Y Growth Comment
China Biologic Products Holdings Inc reported Revenue growth of 7.9% year on year in the fourth quarter 2019, to $ 503.74 millions, this is lower than China Biologic Products Holdings Inc 's recent average Revenue increase of 17.12%.

Looking into fourth quarter 2019 results within Biotechnology & Pharmaceuticals industry 29 other companies have achieved higher Revenue growth. While China Biologic Products Holdings Inc ' s Revenue increase of 7.9% ranks overall at the positon no. 1690 in the fourth quarter 2019.


CBPO Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December 7.9 % 26.04 % 377.15 % 13.69 %
3rd Quarter September - - - 9.88 %
2nd Quarter June - - -2.34 % 15.62 %
1st Quarter March - - 6.85 % 21.66 %
FY   7.9 % -15.29 % 61.54 % -

Financial Statements
China Biologic Products Holdings Inc 's fourth quarter 2019 Revenue $ 503.74 millions CBPO's Income Statement
China Biologic Products Holdings Inc 's fourth quarter 2018 Revenue $ 466.88 millions Quarterly CBPO's Income Statement


CBPO Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - - - -10.29 %
3rd Quarter September - - - -5.35 %
2nd Quarter June - - -2.37 % 6.81 %
1st Quarter March - - 17.8 % 25.35 %
FY (Year on Year)   7.9 % -15.29 % 61.54 % -


Back to CBPO Growth rate Comparisons >> Back to CBPO Growth rate Comparisons >>


Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #291
Overall #1690

Revenue Y/Y Growth Statistics
High Average Low
377.12 % 17.12 % -100 %
(Dec 31 2017)   0
Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #291
Overall #1690
Revenue Y/Y Growth Statistics
High Average Low
377.12 % 17.12 % -100 %
(Dec 31 2017)   0

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

China Biologic Products Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CBPO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CBPO's IV. Quarter Q/Q Revenue Comment


China Biologic Products Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2019)		 12 Months Ending
0		 12 Months Ending
0		 12 Months Ending
0		 12 Months Ending
(Dec 31 2018)
Cumulative Revenue 12 Months Ending $ 503.74 $ 0.00 $ 0.00 $ 0.00 $ 466.88
Y / Y Revenue Growth (TTM) 7.9 % - - - 26.04 %
Year on Year Revenue Growth Overall Ranking # 1565 # 0 # 0 # 0 # 819
Seqeuential Revenue Change (TTM) 7.9 % - - - 26.04 %
Seq. Revenue Growth (TTM) Overall Ranking # 2645 # 0 # 0 # 0 # 275


Cumulative Revenue growth Comment
Although China Biologic Products Holdings Inc 's Annual Revenue growth year on year were below company's average 37.13% , Revenue announced in the Dec 31 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 7.9% year on year, from % in 0.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1565.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 252
Overall # 1565

Revenue TTM Y/Y Growth Statistics
High Average Low
377.12 %
 37.13 %
6.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 349
S&P 500 # 2645
Cumulative Revenue growth Comment
Although China Biologic Products Holdings Inc 's Annual Revenue growth year on year were below company's average 37.13% , Revenue announced in the Dec 31 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 7.9% year on year, from % in 0.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1565.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 252
Overall # 1565

Revenue TTM Y/Y Growth Statistics
High Average Low
377.12 %
37.13 %
6.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 349
S&P 500 # 2645




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CBPO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2019
Correvio Pharma Corp 13.81%$ 13.810 millions
Cardiovascular Systems Inc 13.50%$ 13.500 millions
Surgalign Holdings Inc 13.41%$ 13.410 millions
Escalon Medical Corp 13.27%$ 13.271 millions
Resmed Inc 13.06%$ 13.064 millions
National Vision Holdings Inc 12.88%$ 12.880 millions
American Renal Associates Holdings Inc 12.67%$ 12.669 millions
Regeneron Pharmaceuticals Inc 12.54%$ 12.538 millions
Ptc Therapeutics inc 12.38%$ 12.380 millions
Avanos Medical Inc 11.71%$ 11.713 millions
Luminex Corporation11.55%$ 11.546 millions
West Pharmaceutical Services Inc 11.38%$ 11.385 millions
Vapotherm Inc 11.33%$ 11.330 millions
Strata Skin Sciences Inc11.22%$ 11.225 millions
Steris Plc11.21%$ 11.206 millions
Surgery Partners Inc 11.13%$ 11.135 millions
Neuronetics Inc 11.01%$ 11.007 millions
Masimo Corp10.93%$ 10.925 millions
Biospecifics Technologies Corp10.90%$ 10.896 millions
Harrow Inc 10.72%$ 10.717 millions
Perrigo Company Plc10.68%$ 10.676 millions
Merit Medical Systems Inc10.58%$ 10.578 millions
Abiomed Inc 10.48%$ 10.481 millions
Anika Therapeutics Inc 10.45%$ 10.447 millions
Biorestorative Therapies Inc 10.34%$ 10.345 millions
Idexx Laboratories Inc10.20%$ 10.204 millions
Hca Healthcare Inc 10.18%$ 10.176 millions
Illumina Inc 9.68%$ 9.677 millions
Pra Health Sciences Inc 9.67%$ 9.675 millions
Incyte Corporation9.65%$ 9.649 millions


About China Biologic Products Holdings Inc Revenue Growth Rates (CBPO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.